Robot-assisted Function-sparing Cystectomy Followed by Modified Orthotopic Ileal Neobladder

Sponsor
Wuhan Union Hospital, China (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05881642
Collaborator
(none)
20
2
27

Study Details

Study Description

Brief Summary

With the same tumor control rate as classic radical cystectomy, radical cystectomy with partial preservation of the prostate and seminal vesicle can effectively preserve penile erection and fertility, improve urinary control rate and shorten hospitalization time. In this project, transurethral resection of the prostate was used to remove part of the prostate, which further reduced the trauma of radical cystectomy and better preserved the nerves and urethral sphincter. Rapid intraoperative examination of resected tissue can provide a basis for the selection of surgical options. Robot-assisted radical cystectomy can perform pelvic lymph node dissection more accurately, preserve neurovascular complex more effectively, and improve the control effect of tumor and the protective effect of sexual function and reproductive function. In view of the shortcomings of the internationally accepted orthotopic ileal neobladder, this study improved the operation according to the physiological and anatomical characteristics, restored the orthophoria of the new bladder, maintained the consistency of physiological anatomy, and minimized the bladder pressure.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Prostate and seminal-sparing Cystectomy
  • Procedure: Conventional Radical Cystoprostatectomy
N/A

Detailed Description

Interventional group:patients undergoing transurethral resection and enucleation of the prostate first, do not open the bladder neck to maintain the integrity of the bladder neck. The enucleated prostate capsule and seminal vesicle are preserved under robotic surgery, and the urinary catheter is stretched during the operation to avoid implantation and metastasis.

Conventional group:patients undergoing conventional robotic radical cystoprostatectomy. All the patients undergoing cystectomy and accept at least 12 months follow up.

Followup: Each patient was evaluated at 3-month intervals for 1 year, at 6- month intervals for 2 to 3 years. Renal ultrasound, biochemical examination and urine culture were done every 3 to 6 months. Pelvic computerized tomography and retro-cystogram were performed 6 months postoperatively and annually thereafter. Urodynamic investigation and cystoscopic examination were done annually.

Postoperative complications were classified as early (90 days or less) and late (greater than 90 days). Early and late complications were subdivided into those related and not related to the neobladder. Major complications were defined as grade III or higher.

Daytime and nighttime continence levels were recorded postoperatively at patient interview. Continence was defined as complete if the patient was dry without a pad, satisfactory if no more than 1 pad was required and poor if the patient used more than 1 pad during the day or night.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
20 participants
Allocation:
Non-Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Robot-assisted Cystectomy With Prostate and Seminal-sparing Technique Followed by Modified Orthotopic Ileal Neobladder
Anticipated Study Start Date :
Oct 1, 2023
Anticipated Primary Completion Date :
Nov 1, 2025
Anticipated Study Completion Date :
Jan 1, 2026

Arms and Interventions

Arm Intervention/Treatment
Experimental: Prostate and seminal-sparing Cystectomy

Patients undergoing transurethral resection and enucleation of the prostate before robot-assisted cystectomy

Procedure: Prostate and seminal-sparing Cystectomy
Adopt endoscopic enucleation technology to preserve the prostate capsule and part of the urinary control support structure to help restore urinary control and erectile functions

Placebo Comparator: Conventional Radical Cystoprostatectomy

Patients undergoing conventional robot-assisted radical cystoprostatectomy

Procedure: Conventional Radical Cystoprostatectomy
According to the consensus standard program, remove the accessory tissues including the bladder,prostate and seminal vesicles

Outcome Measures

Primary Outcome Measures

  1. Post-operative urinary function [During each follow-up postoperatively, the assessment is evaluated 36 months postoperatively]

    Assess post-operative urinary function

Secondary Outcome Measures

  1. bladder cancer specific survival rate [During each follow-up postoperatively, the assessment is calculated based on the 36 months result postoperatively]

    Determine bladder cancer control as measured by margin status and time to disease recurrence

  2. Sexual function [During each follow-up postoperatively, the assessment is calculated based on the BCI score of 36 months postoperatively]

    Assess post-operative sexual function

Eligibility Criteria

Criteria

Ages Eligible for Study:
20 Years to 70 Years
Sexes Eligible for Study:
Male
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Muscle invasive or recurrent multiple non-muscle invasive bladder cancer patients

  2. Invasive bladder cancer patients without invasion of the triangle and posterior urethra

  3. Age < 70 years old, urethral sphincter function is good

  4. Male patients with serum prostate specific antigen < 4ug / L

Exclusion Criteria:
  1. Possible recurrence of urethra after cystectomy

  2. Patients with bladder adenocarcinoma and squamous cell carcinoma should not undergo orthotopic neobladder.

  3. Patients with renal insufficiency

  4. Severe liver dysfunction

  5. Severe intestinal diseases ( Crohn 's disease, short bowel syndrome )

  6. Preoperative tumor breaks through the bladder and invades the surrounding tissue

  7. urethral stricture cannot pass through the resectoscope

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Wuhan Union Hospital, China

Investigators

  • Principal Investigator: Xiaoping Zhang, Wuhan Union Hospital, China

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Wuhan Union Hospital, China
ClinicalTrials.gov Identifier:
NCT05881642
Other Study ID Numbers:
  • 0857-01
First Posted:
May 31, 2023
Last Update Posted:
May 31, 2023
Last Verified:
Apr 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No

Study Results

No Results Posted as of May 31, 2023